Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery

What this Trial Is About

This research aims to understand how the release of specific heart-related proteins, called cardiac biomarkers (troponin I, troponin T, and CK-MB), relates to actual heart muscle damage in patients undergoing heart valve surgery. The study focuses on patients without significant coronary artery disease and seeks to clarify how these biomarkers compare in their timing and levels after surgery. Findings may influence international guidelines on diagnosing heart damage after cardiac procedures. The study observes patients having isolated aortic or mitral valve surgery and measures the release of the three cardiac biomarkers during the recovery period. It compares these biomarker levels with traditional diagnostic methods like clinical symptoms, ECG, echocardiography, and advanced heart imaging using magnetic resonance imaging (LGE-cMRI). The imaging is done before surgery and five days afterward to detect any heart muscle injury. Participants will undergo clinical evaluations, ECGs, echocardiography, and blood tests to track biomarker levels around the surgery. They will also have magnetic resonance imaging before surgery and at five days post-surgery to visualize heart muscle damage. Researchers will analyze how the biomarker releases correlate with imaging findings and clinical assessments. The study helps improve understanding of heart injury detection during and after valve surgery and lasts through the immediate postoperative period.

Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery